Status:
COMPLETED
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
Lead Sponsor:
fan li
Conditions:
Colon Cancer
Immunotherapy
Eligibility:
All Genders
18-70 years
Brief Summary
To compare the efficacy and safety of tirellizumab combined with anlotinib in the treatment of mss colorectal cancer. To investigate the effective biomarker of anlotinib combined with tiralizumab
Detailed Description
This was a multicenter retrospective cohort study to compare the efficacy of tyrosine kinase inhibitor（TKI） combined with immune checkpoint inhibitors(ICIs) versus tyrosine kinase inhibitor alone in t...
Eligibility Criteria
Inclusion
- 18-70 years old
- Patients with mss colorectal cancer who have been confirmed by pathology and have relapsed or failed multiline therapy
- Patients who have been treated with anlotinib monotherapy(12 mg qd, d1-14; 21 days per cycle) or anlotinib(12 mg qd, d1-14; 21 days per cycle)+ tislelizumab(200 mg, once every 3 weeks)
- the presence of at least one measurable target lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Exclusion
- Patients with other malignant tumors
- Prior treatment with antirotinib, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibodies or any other antibody or drug that specifically targets T cell co-stimulation or checkpoint pathways
- Follow-up was less than 30 days
Key Trial Info
Start Date :
May 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2024
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT06573424
Start Date
May 1 2024
End Date
October 31 2024
Last Update
May 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Daping Hospital, Third Military Medical University
Chongqing, China, 400042